NEU

1.10%

$13.76 neuren pharmaceuticals limited

Pipeline-in-a-drug, page-139

First 139 Last

Share
Profile

Follow
Anydaynow

1,850 Posts.

441

05/06/24

06:32

Post #: 74166190
Share

Originally posted by giarc63: ↑

For Acadia to develop trofinetide for an indication just to preclude Neuren from developing NNZ2591 for the same indication is absurd.

The cost alone for Acadia to do that would be phenominal. I am not saying that Acadia does not have the right to progress trofinetide in any indication that it wishes to, but the likelihood of trofinetide to pass all the regulatory requirements is far less than the likelihood that the "superior drug" NNZ2591 would.

The sheer cost of Acadia doing this would drive them out of business.

Acadia is much better suited to progress NNZ2591 for Retts and Fragile-X and I have been waiting for that announcement to drop since the last agreement was signed with Neuren. John keeps saying that decision is totally up to Acadia. I believe also that John does not believe that Acadia would promote trofinetide in any undisclosed indication just to preclude Neuren from doing ii with NNZ2591. The cost alone of doing that should stop Acadia in its tracks.

Once again - the relationship between Acadia and Neuren has been convivial to this date and there is no reason to belive that it will not continue to be so.

The recent back track in the share price for Acadia can be attributed more to its failure with another drug and not to the preformance of Daybue/trofinetide.

Acadia Pharmaceuticals (NASDAQ:ACAD) faced a sharp decline this year after deciding not to proceed with further trials for pimavanserin, a drug aimed at treating schizophrenia, and now its outlook looks bleak or at least unfavorable.

Although the Daybue sales came in the lower ebb of the expected sales - Daybue/Trofinetide continues to serve its purpose for Neuren.

The future for Neuren definitely lies with NNZ2591 and I see no reason for concern as to the ability of NNZ2591 to treat multiple neurological indications. That is the scientific aim for this drug.

I also cannot see that Acadia would ever target an indication just to preclude Neuren from doing so, it cuts against the grain that they would ever consider doing that, let alone be able to afford to do so - in reality. That would be absurd.

Expand

I agree Giarc, just when NEU is seeing blue sky on it’s horizon with nary a cloud in sight HC posters are seeing smoke and mirrors.
FWIW I wouldn’t be surprised to see a takeover of both ACAD and NEU by a much much bigger BP, it would simplify the whole process and give an immediate revenue return in Trof without the need to pay royalties to NEU. IMHO NEU is worth at least x5 the price of ACAD.

NEU Price at posting: $19.02 Sentiment: Buy Disclosure: Held
18 Upvote

0 Great analysis

Reply

Top Stories

MLS

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

MM8

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

AZY

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

VUL

Vulcan appoints investment bank and M&A veteran to board

ENV

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

ASN

Utah authorities sign off on Anson's lithium extraction plans at Green River

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

NAM

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

MKG

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

There are more pages in this discussion • 50 more messages in this thread...

First 139 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $13.76		Change 0.150(1.10%)		Mkt cap ! $1.758B

Open	High	Low	Value	Volume
$13.60	$14.00	$13.51	$5.043M	365.4K

Buyers (Bids)

No.	Vol.	Price($)
1	3816	$13.73

Sellers (Offers)

Price($)	Vol.	No.
$13.78	2834	1

View Market Depth

No.	Vol.	Price($)
1	3816	13.730
3	3430	13.720
1	1582	13.710
1	1807	13.690
1	1807	13.670

Price($)	Vol.	No.
13.780	2834	1
13.840	1623	2
13.870	1807	1
13.890	1807	1
13.910	1807	1

Last trade - 16.10pm 13/09/2024 (20 minute delay)

NEU (ASX) Chart

Pipeline-in-a-drug, page-139

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Vulcan appoints investment bank and M&A veteran to board

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Utah authorities sign off on Anson's lithium extraction plans at Green River

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Pipeline-in-a-drug, page-139

Top Stories

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Vulcan appoints investment bank and M&A veteran to board

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Utah authorities sign off on Anson's lithium extraction plans at Green River

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News